Targeting the Hidden Genetic Heart Risk
Advanced Heart & Vascular Institute of Hunterdon is enrolling qualified patients in the Ocean(a) Clinical Trial studying a novel therapy to reduce Lipoprotein(a).
What is Lp(a)?
Lipoprotein(a), or Lp(a), is a genetically inherited cholesterol particle that significantly increases the risk of:
- Heart attack
- Stroke
- Aortic stenosis
- Peripheral artery disease
Unlike LDL cholesterol, Lp(a) levels are largely determined by genetics and cannot be reduced with diet or exercise.
Many patients have elevated Lp(a) and don’t know it.
Why This Trial Matters
Current medications do not effectively lower Lp(a).
The Ocean(a) Clinical Trial is evaluating an investigational RNA-based therapy designed to:
- Specifically target Lp(a) production
- Reduce circulating Lp(a) levels
- Potentially lower long-term cardiovascular risk
This represents one of the most promising developments in preventive cardiology.
Who May Qualify?
You may qualify if you:
- Have elevated Lp(a) levels
- Have known coronary or vascular disease
- Have a family history of premature heart disease
- Are between eligible age criteria (per protocol)
Eligibility is determined through screening.
Why AHVI?
Led by Dr. Andrey Espinoza, Principal Investigator with extensive experience in cardiovascular research, AHVI has participated in numerous national and international cardiovascular trials.
Our research suite provides:
- Dedicated research coordinators
- On-site cardiovascular imaging
- Office-based lab capabilities
- Comprehensive risk evaluation
Patients receive close monitoring throughout participation.
What to Expect
If eligible:
- Screening visit
- Study medication administration (per protocol)
- Routine follow-up visits
- No-cost study-related care
Compensation may be available for time and travel.
Elevated Lp(a) could be silently increasing your cardiovascular risk.
Take the next step.
OR
Call Research Team at 908-291-3405